# Preoperative MPDL3280A in Transitional Cell Carcinoma of the Bladder

> **NCT02662309** · PHASE2 · COMPLETED · sponsor: **Queen Mary University of London** · enrollment: 96 (actual)

## Conditions studied

- Bladder Cancer

## Interventions

- **DRUG:** MPDL3280A

## Key facts

- **NCT ID:** NCT02662309
- **Lead sponsor:** Queen Mary University of London
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02-01
- **Primary completion:** 2020-06-11
- **Final completion:** 2020-06-11
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2025-03-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02662309

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02662309, "Preoperative MPDL3280A in Transitional Cell Carcinoma of the Bladder". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02662309. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*